Classes
DEA Class; Rx
Common Brand Names; Venofer
- Iron Products
Description
IV iron supplement and oral phosphate binder
Used IV for the treatment of iron deficiency anemia in patients with chronic kidney disease and orally for control of serum phosphorus levels in patients with chronic kidney disease on dialysis
Can cause serious, even fatal, hypersensitivity reactions when administered IV; although less likely to cause hypersensitivity than iron dextran, facilities for cardiopulmonary resuscitation must be available during dosing
Indications
Indicated for the treatment of iron-deficiency anemia in patients with chronic kidney disease.
Indicated for treatment of iron deficiency anemia associated with chronic kidney disease
Contraindications
Hypersensitivity
Anemia not caused by iron deficiency
Iron overload
Adverse Effects
- Hypotension (36%)
- Muscle cramps (23%)
- Headache
- Nausea
- Dizziness
- Fatigue
- Arthralgia
- Back pain
- Hypertension
- Fluid overload
- Peripheral edema
- Cough
- Vomiting
- Diarrhea
- Constipation
- Pruritus
Warnings
Risk of hypotension
Withhold therapy in tissue iron overload
Hypersensitivity
- Serious hypersensitivity reactions reported, including anaphylactic-type reactions, some of which have been life-threatening and fatal
- Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse
- If hypersensitivity reactions or signs of intolerance occur during administration, stop infusion immediately
- Monitor patients for signs and symptoms of hypersensitivity during and after administration for at least 30 minutes and until clinically stable following completion of the infusion
Pregnancy and Lactation
Published studies on intravenous iron sucrose treatment after first trimester of pregnancy not shown adverse maternal or fetal outcomes
Iron sucrose is present in human milk, and available published reports following exposure to 100-300 mg intravenous iron sucrose have not reported adverse reactions in breastfed infants; there are no data on effects on milk production
Maximum Dosage
500 mg/dose IV has been administered on 2 consecutive days in patients with chronic kidney disease. Up to 3000 mg/day PO has been studied in patients with end stage renal disease.
500 mg/dose IV has been administered on 2 consecutive days in patients with chronic kidney disease. Up to 3000 mg/day PO has been studied in patients with end stage renal disease.
0.5 mg/kg IV up to a max of 100 mg/dose IV. Safety and efficacy of iron sucrose chewable tablets have not been established.
>= 2 years: 0.5 mg/kg IV up to a max of 100 mg/dose IV. Safety and efficacy of iron sucrose chewable tablets have not been established.
< 2 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Iron sucrose
injectable solution
- 20mg (Fe)/mL
